Pitango is one of Israel’s longest standing venture capital firms and one of the country’s most active technology investors. With more than 300 portfolio companies and around 100 exits across three decades, Pitango has become a central institution in Israel’s innovation ecosystem. The firm invests across multiple categories including deep tech, AI, healthtech and next generation infrastructure, and today holds the largest number of Israeli portfolio companies generating more than $100 million in annual revenue.
Pitango has closed $300 million across two new early stage vehicles: Pitango First and Pitango HealthTech. These funds reinforce the firm’s leadership in Israel’s seed and early stage markets, particularly during a period of high demand for institutional capital in deep tech and healthcare.
Pitango First is the firm’s early stage technology fund led by Eyal Niv, Dr. Ayal Itzkovitz, Gad Huldai and Yair Cassuto. The fund is already investing in AI, infrastructure, quantum, cybersecurity and cloud, supporting both experienced operators and first time founders. Investments such as AAI, GammaTime and Apprentice.AI exemplify its focus on foundational technologies and next generation computing capabilities.
Pitango HealthTech, led by Ittai Harel, Hila Karah and Dr. Jonathan Glazer, continues the firm’s specialization in digital health, AI driven diagnostics, medical devices and therapeutics. The fund has already achieved notable outcomes including the exit of Vertos and the IPO of TScan, and has built a new investment model to accelerate capital allocation into its core healthcare verticals.
Both funds reflect a period of strong performance for Pitango, following milestones such as the IPO of Via, PsiQuantum’s $1 billion funding round and multiple strategic acquisitions in the portfolio.
Leadership
Pitango First is led by Eyal Niv, Dr. Ayal Itzkovitz, Gad Huldai and Yair Cassuto.
Pitango HealthTech is led by Ittai Harel, Hila Karah and Dr. Jonathan Glazer.
The broader Pitango partnership includes experienced investors with deep roots in Israeli technology, healthcare innovation and global company building.
Investment Strategy
Pitango follows a founder centered investment strategy focused on identifying breakthrough technologies early and supporting teams from seed through scale.
The firm emphasizes high conviction bets, board level involvement, deep technical diligence and long term partnership.
Pitango First prioritizes infrastructure, AI, cybersecurity and quantum companies, while Pitango HealthTech focuses on digital health, clinical innovation, medical devices and pharma. Across both funds, Pitango supports founders through regulatory navigation, market access, scaling operations and global expansion.
Notable Investments
Pitango has invested in more than 300 companies including:
The portfolio includes several of Israel’s fastest scaling AI, infrastructure and digital health companies.
Notable Exits
Notable exits include the IPO of Via, the IPO of TScan, the acquisition of Vertos, and liquidity events across companies such as Riskified, Taboola and additional portfolio leaders.
Other
Pitango remains one of Israel’s most influential venture firms and continues to lead the market in AI and quantum investments.
Nechemia (Chemi) J. Peres - Managing Partner & Co-Founder
chemi.p@pitango.com
Rami Kalish - Managing Partner & Co-Founder
rami.k@pitango.com
Israel
